These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 27994288)

  • 1. Plasma Cathepsin S and Cathepsin S/Cystatin C Ratios Are Potential Biomarkers for COPD.
    Nakajima T; Nakamura H; Owen CA; Yoshida S; Tsuduki K; Chubachi S; Shirahata T; Mashimo S; Nakamura M; Takahashi S; Minematsu N; Tateno H; Fujishima S; Asano K; Celli BR; Betsuyaku T
    Dis Markers; 2016; 2016():4093870. PubMed ID: 27994288
    [No Abstract]   [Full Text] [Related]  

  • 2. Relationship between plasma cathepsin S and cystatin C levels and coronary plaque morphology of mild to moderate lesions: an in vivo study using intravascular ultrasound.
    Gu FF; Lü SZ; Chen YD; Zhou YJ; Song XT; Jin ZN; Liu H
    Chin Med J (Engl); 2009 Dec; 122(23):2820-6. PubMed ID: 20092784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The association between Cathepsin S and pulmonary function and CT phenotypes in patients with chronic obstructive pulmonary disease].
    Wu KY; Zhu Z; Wang Y; Yin SJ; Li GY; Kong ZB; Liu Y; Li H; Song S; Liu H
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 May; 42(5):372-377. PubMed ID: 31137114
    [No Abstract]   [Full Text] [Related]  

  • 4. Acute phase serum cathepsin S level and cathepsin S/cystatin C ratio are the associated factors with cerebral infarction and their diagnostic value for cerebral infarction.
    Zhang AW; Han XS; Xu XT; Fang YN; Chen HB; Jiang T
    Kaohsiung J Med Sci; 2019 Feb; 35(2):95-101. PubMed ID: 30848029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased serum cathepsin S in patients with atherosclerosis and diabetes.
    Liu J; Ma L; Yang J; Ren A; Sun Z; Yan G; Sun J; Fu H; Xu W; Hu C; Shi GP
    Atherosclerosis; 2006 Jun; 186(2):411-9. PubMed ID: 16140306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cystatin C as a Predictor of In-Hospital Mortality After Exacerbation of COPD.
    Hu G; Wu Y; Zhou Y; Yu Y; Liang W; Ran P
    Respir Care; 2016 Jul; 61(7):950-7. PubMed ID: 27072013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.
    Tumminello FM; Flandina C; Crescimanno M; Leto G
    Biomed Pharmacother; 2008 Feb; 62(2):130-5. PubMed ID: 17728092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Cystatin C as an Inflammatory Marker in Exacerbated and Convalescent COPD Patients.
    Zhang M; Li Y; Yang X; Shan H; Zhang Q; Ming Z; Xie Y; Chen H; Liu Y; Zhang J
    Inflammation; 2016 Apr; 39(2):625-31. PubMed ID: 26613760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cathepsin S and cystatin C levels and risk of abdominal aortic aneurysm: a randomized population-based study.
    Lv BJ; Lindholt JS; Cheng X; Wang J; Shi GP
    PLoS One; 2012; 7(7):e41813. PubMed ID: 22844527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum cathepsin S and cystatin C: relationship to subclinical carotid atherosclerosis in rheumatoid arthritis.
    Tejera-Segura B; de Vera-González AM; López-Mejías R; González-Gay MA; Ferraz-Amaro I
    Clin Exp Rheumatol; 2016; 34(2):230-5. PubMed ID: 26941186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cathepsin B, cathepsin H, cathepsin X and cystatin C in sera of patients with early-stage and inflammatory breast cancer.
    Decock J; Obermajer N; Vozelj S; Hendrickx W; Paridaens R; Kos J
    Int J Biol Markers; 2008; 23(3):161-8. PubMed ID: 18949742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MFG-E8, a clearance glycoprotein of apoptotic cells, as a new marker of disease severity in chronic obstructive pulmonary disease.
    Zhang S; Xie JG; Su BT; Li JL; Hu N; Chen J; Luo GW; Cui TP
    Braz J Med Biol Res; 2015 Nov; 48(11):1032-8. PubMed ID: 26375445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Expression of Cathepsin E is Associated with the Severity of Airflow Limitation in Patients with COPD.
    Cao WJ; Li MH; Li JX; Xu X; Ren SX; Rajbanshi B; Xu JF
    COPD; 2016; 13(2):160-6. PubMed ID: 26488201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis.
    Haves-Zburof D; Paperna T; Gour-Lavie A; Mandel I; Glass-Marmor L; Miller A
    J Cell Mol Med; 2011 Nov; 15(11):2421-9. PubMed ID: 21143385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of chronic kidney diseases in patients with chronic obstructive pulmonary disease: assessment based on glomerular filtration rate estimated from creatinine and cystatin C levels.
    Yoshizawa T; Okada K; Furuichi S; Ishiguro T; Yoshizawa A; Akahoshi T; Gon Y; Akashiba T; Hosokawa Y; Hashimoto S
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1283-9. PubMed ID: 26185434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of occult parechymal disease such as emphysema or airway disease using screening computed tomography.
    Tsushima K; Sone S; Fujimoto K; Kubo K; Morita S; Takegami M; Fukuhara S
    COPD; 2010 Apr; 7(2):117-25. PubMed ID: 20397812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Utility of Biomarkers in COPD.
    Ambade VN; Sontakke AN; Barthwal MS; Tyagi R; Basannar DR
    Respir Care; 2015 Dec; 60(12):1729-42. PubMed ID: 26106205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Ratio Serum Creatinine/Serum Cystatin C (a Surrogate Marker of Muscle Mass) as a Predictor of Hospitalization in Chronic Obstructive Pulmonary Disease Outpatients.
    Amado CA; García-Unzueta MT; Lavin BA; Guerra AR; Agüero J; Ramos L; Muñoz P
    Respiration; 2019; 97(4):302-309. PubMed ID: 30481791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma sE-cadherin and the plasma sE-cadherin/sVE-cadherin ratio are potential biomarkers for chronic obstructive pulmonary disease.
    Shirahata T; Nakamura H; Nakajima T; Nakamura M; Chubachi S; Yoshida S; Tsuduki K; Mashimo S; Takahashi S; Minematsu N; Tateno H; Asano K; Fujishima S; Betsuyaku T
    Biomarkers; 2018 Jul; 23(5):414-421. PubMed ID: 29376431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression and significance of hypoxia-inducible factor-1α in patients with chronic obstructive pulmonary disease and smokers with normal lung function].
    Tao H; Luo W; Pei H; Zhu S; Zhang M; Chen B; He J; Zhang M; Zhou R
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Aug; 30(8):852-5. PubMed ID: 25108440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.